200 related articles for article (PubMed ID: 16632329)
1. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial.
Emsley R; Niehaus DJ; Koen L; Oosthuizen PP; Turner HJ; Carey P; van Rensburg SJ; Maritz JS; Murck H
Schizophr Res; 2006 May; 84(1):112-20. PubMed ID: 16632329
[TBL] [Abstract][Full Text] [Related]
2. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study.
Lerner V; Miodownik C; Kaptsan A; Bersudsky Y; Libov I; Sela BA; Witztum E
J Clin Psychiatry; 2007 Nov; 68(11):1648-54. PubMed ID: 18052557
[TBL] [Abstract][Full Text] [Related]
3. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
[TBL] [Abstract][Full Text] [Related]
6. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
Bai YM; Yu SC; Lin CC
J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
[TBL] [Abstract][Full Text] [Related]
7. Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial.
Emsley R; Niehaus DJ; Oosthuizen PP; Koen L; Ascott-Evans B; Chiliza B; van Rensburg SJ; Smit RM
Psychiatry Res; 2008 Dec; 161(3):284-91. PubMed ID: 18962989
[TBL] [Abstract][Full Text] [Related]
8. Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug.
Li CR; Chung YC; Park TW; Yang JC; Kim KW; Lee KH; Hwang IK
World J Biol Psychiatry; 2009; 10(4 Pt 3):919-24. PubMed ID: 19995222
[TBL] [Abstract][Full Text] [Related]
9. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
[TBL] [Abstract][Full Text] [Related]
10. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis.
Small JG; Milstein V; Marhenke JD; Hall DD; Kellams JJ
J Clin Psychiatry; 1987 Jul; 48(7):263-7. PubMed ID: 2885310
[TBL] [Abstract][Full Text] [Related]
11. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia.
Emsley R; Myburgh C; Oosthuizen P; van Rensburg SJ
Am J Psychiatry; 2002 Sep; 159(9):1596-8. PubMed ID: 12202284
[TBL] [Abstract][Full Text] [Related]
12. Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial.
Berger GE; Proffitt TM; McConchie M; Yuen H; Wood SJ; Amminger GP; Brewer W; McGorry PD
J Clin Psychiatry; 2007 Dec; 68(12):1867-75. PubMed ID: 18162017
[TBL] [Abstract][Full Text] [Related]
13. Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study.
Lerner V; Miodownik C; Kaptsan A; Cohen H; Matar M; Loewenthal U; Kotler M
Am J Psychiatry; 2001 Sep; 158(9):1511-4. PubMed ID: 11532741
[TBL] [Abstract][Full Text] [Related]
14. Vitamin E in the treatment of tardive dyskinesia.
Akhtar S; Jajor TR; Kumar S
J Postgrad Med; 1993; 39(3):124-6. PubMed ID: 7914238
[TBL] [Abstract][Full Text] [Related]
15. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study.
Chouinard G
J Clin Psychopharmacol; 1995 Feb; 15(1 Suppl 1):36S-44S. PubMed ID: 7537286
[TBL] [Abstract][Full Text] [Related]
16. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study.
Nasrallah HA; Silva R; Phillips D; Cucchiaro J; Hsu J; Xu J; Loebel A
J Psychiatr Res; 2013 May; 47(5):670-7. PubMed ID: 23421963
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
18. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S
J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
[TBL] [Abstract][Full Text] [Related]
19. Naltrexone treatment of tardive dyskinesia in patients with schizophrenia.
Wonodi I; Adami H; Sherr J; Avila M; Hong LE; Thaker GK
J Clin Psychopharmacol; 2004 Aug; 24(4):441-5. PubMed ID: 15232337
[TBL] [Abstract][Full Text] [Related]
20. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
Silver H; Geraisy N; Schwartz M
J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
